Navigation Links
Boehringer Ingelheim Unveils Diabetes Pipeline
Date:6/6/2009

eline to week 12.(1) Out of the 333 randomized patients, 268 patients received double-blind treatment with linagliptin (1 mg, n=65; 5 mg, n=66; 10 mg, n=66) or placebo.(1) An open-label arm with 65 patients on glimepiride was added for descriptive control.(1)

Additional results from the study

The addition of linagliptin to metformin treatment for 12 weeks resulted in clinically relevant and statistically significant reductions in HbA1c and fasting blood sugar or fasting plasma glucose (FPG) levels (p-values of less than 0.05%):(1)

  • Statistically significant reductions in mean HbA1c levels with linagliptin 5 mg and 10 mg compared with metformin alone (both p<0.001) were observed from week four though week 12.(1)
  • In addition, all linagliptin doses showed significant reductions in FPG levels compared with metformin alone (placebo-corrected mean changes from baseline; -19.2 mg/dL for 1 mg, -34.7 mg/dL for 5 mg, and -29.0 mg/dL for 10 mg).(1)
  • In the open-label comparator arm, the placebo-corrected mean change from baseline in HbA1c was -0.90 percent.(1)
  • More than 85% of the patients receiving the 5mg and 10mg doses of linagliptin demonstrated greater that or equal to 80% DPP-4 inhibition at trough at week 12(1)
  • HbA1c reductions of at least 0.5 percent were achieved in 44 percent to 53 percent of patients on linagliptin, but only in 13 percent of the patients receiving metformin alone.(1)

About type 2 diabetes

There are approximately 23.6(5) million Americans and 246 million people worldwide(6) with diabetes. Type 2 diabetes is the most common type of diabetes accounting for more than 90% of all diabetes cases in the developed world.(7) Every ten seconds two people develop diabetes and one person dies from diabetes-related causes around the world.(6) Each
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
5. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
8. Oregon Tourism Commission Unveils New Online Customer Service Training Program
9. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... World Drug Safety Congress in Boston, MA, ePharmaSolutions announced ... system to support the most recent national and local ... advanced distribution and tracking capabilities. The distribution ... and time consuming process for global biopharmaceutical companies who ...
... The Female Health Company (NASDAQ-CM: FHCO), today announced that its ... $0.05 per share.  The dividend is payable May 10, 2011 ... In January, 2010, the Company announced the initiation of ... dividends since the program,s inception. "The Company,s Board ...
Cached Medicine Technology:ePharmaSolutions Launches Major Release of Its Global Safety Letter Distribution and Tracking Application in More Than 90 Countries 2The Female Health Company Declares 2nd Quarter Dividend of $0.05/share 2The Female Health Company Declares 2nd Quarter Dividend of $0.05/share 3
(Date:7/13/2014)... York (PRWEB) July 13, 2014 A ... attention to the cancer risks associated with power morcellators ... tell their story to federal regulators, as they presented ... U.S. Food & Drug Administration (FDA) advisory panel meeting ... According to the Rochester Democrat and Chronicle, Dr. ...
(Date:7/13/2014)... 13, 2014 Athletes with a certain ... from concussions, according to research presented today at the ... Annual Meeting. The research marks the first of its ... the known physical events that occur after a head ... long allele in the (GT)n genotype were four times ...
(Date:7/13/2014)... Trujillo Alto, Puerto Rico (PRWEB) July 13, 2014 ... that NBA Hall of Famer, Chris Mullin, will be ... Meeting on Saturday, July 26th in Puerto Rico. ... opportunities. Chris Mullin will participate in two exhibition basketball ... Max International, the ultimate supplier of health- and ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review recently ... on what to do to eliminate the root cause ... its review that readers can easily learn what foods to ... health. Vkool also informs in its Kidney Disease Solution review ... functions naturally. The book consists of a collection of natural ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3
... Feb. 15 (HealthDay News) -- The number of needlestick/sharps-related ... the United States has fallen since a federal safety ... Needlestick Safety and Prevention Act (NSPA) requires employers to ... for exposure to bloodborne pathogens and to let frontline ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) ... don,t require driver,s education before getting a license, about ... than half fail to undergo any formal behind-the-wheel training. ... academic records were especially unlikely to have received driver,s ...
... 15 (HealthDay News) -- How fast you walk or how strong ... for dementia or stroke later in life, a new study suggests. ... in a doctor,s office, noted study author Dr. Erica C. Camargo, ... the walking speed, hand grip strength and cognitive function of more ...
... with birth defects who are born on weekends or at night ... new study says. Both groups of infants stayed at the ... of admission to the neonatal intensive care unit, and required antibiotics ... from the University of Rochester Medical Center in New York. ...
... and their colleagues have provided the first evidence of a ... to post-traumatic stress disorder. Their new study, ... Psychology , also suggests that people who suffer even a ... anxiety disorder and should take precautions to avoid stressful situations ...
... -- According to a new study, smoking causes the body ... vulnerable to disease. Despite the daily disturbance of ... a stable ecosystem of healthy bacteria. New research shows that ... diverse ecosystemand is much more susceptible to invasion by harmful ...
Cached Medicine News:Health News:'Needlestick' Law Linked to Drop in Health Worker Injuries 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 3Health News:Can Walking Speed, Hand Grip in Middle Age Predict Dementia Risk? 2Health News:Weekend Delivery Doesn't Hurt Babies With Birth Defects: Study 2Health News:UCLA scientists report link between traumatic brain injury, post-traumatic stress disorder 2Health News:In the mouth, smoking zaps healthy bacteria, welcomes pathogens 2Health News:In the mouth, smoking zaps healthy bacteria, welcomes pathogens 3
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
... Durable ergonomic chairs with concave seats and ... options like seats, backrests, armrests, and casters ... for top performance in a variety of ... static control, health care and office. • ...
Medicine Products: